Blood flow regulating Macrophages, the science behind the scalable iLP-technology platform and lead candidate ILP100 published in Circulation Research
Our CEO Evelina Vågesjö is listed for Advanced therapies by the TheMedicineMaker together with the former Head och Cell- and Genetherapies at Novartis bringing the first CAR T cell therapy to market and the recent Nobel Laureates and users of the CRISPER technology. The ILP-drug candidates and the lead candidate ILP100 developed in Topical and Oral formulations is indeed advanced therapy, it is a next generation immunotherapy and are developed to treat wounds in skin and mucosa.
Extended data released by Ilya Pharma from the first in human trial WHILYAS-1.
Immunology week hosted by Swedish TV, Malou efter 10. Mia Phillipson, Professor in physiology at Uppsala University and co-founder of Ilya Pharma gives an update of what immune cells do in the body during homeostasis and how they heal wounds in skin and mucosa. In Swedish.